

1. References

1. Mullard, A. (2021) “Pfizer’s COVID-19 vaccine secures first full FDA approval,” *Nature Reviews Drug Discovery*, 20(10), pp. 728–728.
2. Addeo, Alfredo, Pankil K. Shah, Natacha Bordry, Robert D. Hudson, Brenna Albracht, Mariagrazia Di Marco, Virginia Kaklamani, et al. 2021. “Immunogenicity of SARS-COV-2 Messenger RNA Vaccines in Patients with Cancer.” *Cancer Cell* 39(8).
3. Rugge, Massimo, Manuel Zorzi, and Stefano Guzzinati. 2020. “SARS-CoV-2 Infection in the Italian Veneto Region: Adverse Outcomes in Patients with Cancer.” *Nature Cancer* 1 (8): 784–88.
4. Saini, Kamal S., Marco Tagliamento, Matteo Lambertini, Richard McNally, Marco Romano, Manuela Leone, Giuseppe Curigliano, and Evandro de Azambuja 2020. “Mortality in Patients with Cancer and Coronavirus Disease 2019: A Systematic Review and Pooled Analysis of 52 Studies.” *European Journal of Cancer* 139: 43–50.
5. Keykhaei, Mohammad, Masood Masinaei, Esmaeil Mohammadi, Sina Azadnajafabad, Negar Rezaei, Sahar Saeedi Moghaddam, Nazila Rezaei, et al. 2021. “A Global, Regional, and National Survey on Burden and Quality of Care Index (QCI) of Hematologic Malignancies; Global Burden of Disease Systematic Analysis 1990–2017.” *Experimental Hematology & Oncology* 10(1).
6. Passamonti, Francesco, Chiara Cattaneo, Luca Arcaini, Riccardo Bruna, Michele Cavo, Francesco Merli, Emanuele Angelucci, et al. 2020 “Clinical Characteristics and Risk Factors

- Associated with COVID-19 Severity in Patients with Haematological Malignancies in Italy: A Retrospective, Multicentre, Cohort Study.” *The Lancet Haematology* 7(10).
7. Kakkassery, Helen, Esme Carpenter, Piers E.M. Patten, and Sheeba Irshad.2022
“Immunogenicity of SARS-COV-2 Vaccines in Patients with Cancer.” *Trends in Molecular Medicine* 28(12): 1082–99.
 8. Herzog Tzarfati, Katrin, Odit Gutwein, Arie Apel, Naomi Rahimi-Levene, Maya Sadovnik, Lotem Harel, Patricia Benveniste-Levkovitz, Adina Bar Chaim, and Maya Koren-Michowitz. 2021. “BNT162b2 COVID-19 Vaccine Is Significantly Less Effective in Patients with Hematologic Malignancies.” *American Journal of Hematology* 96 (10): 1195–1203.
 9. Agha, Mounzer E, Maggie Blake, Charles Chilleo, Alan Wells, and Ghady Haidar.2021.
“Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients with Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.” *Open Forum Infectious Diseases* 8(7).
 10. Mair, Maximilian J., Julia M. Berger, Manfred Mitterer, Margaretha Gansterer, Arne C. Bathke, Wolfgang Trutschnig, Anna S. Berghoff, et al. 2022. “Third Dose of SARS-COV-2 Vaccination in Hemato-Oncological Patients and Health Care Workers: Immune Responses and Adverse Events – a Retrospective Cohort Study.” *European Journal of Cancer* 165: 184–94.
 11. “Covid-19 Vaccines for People Who Are Moderately or Severely Immunocompromised.” Centers for Disease Control and Prevention. Centers for Disease Control and Prevention.

Accessed January 24, 2023.

<https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/immuno.html>.

12. Teh, Joanne S., Julien Coussement, Zoe C. Neoh, Tim Spelman, Smaro Lazarakis, Monica A. Slavin, and Benjamin W. Teh. 2022. “Immunogenicity of COVID-19 Vaccines in Patients with Hematologic Malignancies: A Systematic Review and Meta-Analysis.” *Blood Advances* 6(7): 2014–34.
13. Bird, Sarah, Aikaterini Panopoulou, Robyn L Shea, Micky Tsui, Radovan Saso, Amit Sud, Sharon West, et al. 2021. “Response to First Vaccination against SARS-COV-2 in Patients with Multiple Myeloma.” *The Lancet Haematology* 8(6).
14. Roeker, Lindsey E., David A. Knorr, Meghan C. Thompson, Mariely Nivar, Sonia Lebowitz, Nicole Peters, Isaac Deonarine, et al. 2021. “COVID-19 Vaccine Efficacy in Patients with Chronic Lymphocytic Leukemia.” *Leukemia* 35 (9): 2703–5.
15. Narita, Kentaro, So Nakaji, Rikako Tabata, Toshiki Terao, Ayumi Kuzume, Takafumi Tsushima, Daisuke Ikeda, et al. 2022. “Antibody Response to COVID-19 Vaccination in Patients with Lymphoma.” *International Journal of Hematology* 115(5): 728–36.
16. Page, Matthew J, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, et al. 2021. “The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews.” *BMJ*, 2021.
17. Ouzzani, Mourad. 2017. “Rayyan — a Web and Mobile App for Systematic Reviews.” *Systematic Reviews*, no. 2016: 1–10.

18. “The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of non randomised studies in meta-analyses” Accessed January 24, 2023.
http://www.evidencebasedpublichealth.de/download/Newcastle_Ottawa_Scale_Pope_Bruce.pdf.
19. Higgins, J. P. 2003. “Measuring Inconsistency in Meta-Analyses.” *BMJ* 327(7414): 557–60.
<https://doi.org/10.1136/bmj.327.7414.557>.
20. “RStudio: Integrated Development Environment for R.” Accessed January 24, 2023.
<https://www.r-project.org/conferences/useR-2011/abstracts/180111-allairejj.pdf>.
21. Egger, M., G. D. Smith, M. Schneider, and C. Minder. 1997. “Bias in Meta-Analysis Detected by a Simple, Graphical Test.” *BMJ* 315(7109): 629–34.
22. Aleman, Adolfo, Bhaskar Upadhyaya, Kevin Tuballes, Katerina Kappes, Charles.R. Gleason, Katherine Beach, Sarita Agte, et al. 2021. “Variable Cellular Responses to SARS-COV-2 in Fully Vaccinated Patients with Multiple Myeloma.” *Cancer Cell* 39(11): 1442–44.
23. Avivi, Irit, Roi Balaban, Tamir Shragai, Gabi Sheffer, Miguel Morales, Anat Aharon, Noa Lowenton-Spier, et al. 2021. “Humoral Response Rate and Predictors of Response to BNT162B2 Mrna COVID19 Vaccine in Patients with Multiple Myeloma.” *British Journal of Haematology* 195(2): 186–93.
24. Bergman, Peter, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Puran Chen, Gunnar Söderdahl, et al. 2021. “Safety and Efficacy of the Mrna BNT162b2 Vaccine against

- SARS-COV-2 in Five Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-Label Clinical Trial.” *eBioMedicine* 74: 103705.
25. Bitoun, Samuel, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, et al. 2021. “Response to COVID-19 mRNA Vaccination in Multiple Myeloma Is Conserved but Impaired Compared to Controls.” *Journal of Hematology and Oncology* 14 (1): 2–5. <https://doi.org/10.1186/s13045-021-01183-2>.
 26. Canti, Lorenzo, Stéphanie Humblet Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, Leo Heyndrickx, Aurélie Henry, et al. 2021. “Predictors of Neutralizing Antibody Response to BNT162b2 Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients,” 1–12. <https://doi.org/10.1186/s13045-021-01190-3>.
 27. Chowdhury, Onima, Hannah Bruguier, Garry Mallett, Nikolaos Sousos, Kirsty Crozier, Caroline Allman, David Eyre, et al. 2021. “Impaired Antibody Response to COVID-19 Vaccination in Patients with Chronic Myeloid Neoplasms.” *British Journal of Haematology* 194 (6): 1010–15. <https://doi.org/10.1111/bjh.17644>.
 28. Chung, David J., Gunjan L. Shah, Sean M. Devlin, Lakshmi V. Ramanathan, Sital Doddi, Melissa S. Pessin, Elizabeth Hoover, et al. 2021. “Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.” *Blood Cancer Discovery* 2 (6): 568–76. <https://doi.org/10.1158/2643-3230.bcd-21-0139>.
 29. Crombie, Jennifer L., Amy C. Sherman, Chi-A n Cheng, Christine E. Ryan, Rebecca Zon, Michaël Desjardins, Peter Baker, et al. 2021. “Activity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies.” *Blood Advances* 5(16): 3062–65.

30. Fiorino, Fabio, Anna Sicuranza, Annalisa Ciabattini, Adele Santoni, Gabiria Pastore, Martina Simoncelli, Jacopo Polvere, et al. 2021. "The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA Sars-COV-2 Vaccine Calls for a Third Dose." *Biomedicines* 9 (10): 2–9. <https://doi.org/10.3390/biomedicines9101480>.
31. Gastinne, Thomas, Amandine Le Bourgeois, Marianne Coste-Burel, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Berthe Marie Imbert, et al. 2022. "Safety and Antibody Response after One and/or Two Doses of BNT162b2 Anti-SARS-CoV-2 mRNA Vaccine in Patients Treated by CAR T Cells Therapy." *British Journal of Haematology* 196 (2): 360–62. <https://doi.org/10.1111/bjh.17818>.
32. Gavriatopoulou, Maria, Evangelos Terpos, Efstathios Kastiris, Alexandros Briasoulis, Sentiljana Gumeni, Ioannis Ntanasis-Stathopoulos, Aimilia D. Sklirou, et al. 2022. "Low Neutralizing Antibody Responses in WM, CLL and NHL Patients after the First Dose of the BNT162b2 and AZD1222 Vaccine." *Clinical and Experimental Medicine* 22 (2): 319–23. <https://doi.org/10.1007/s10238-021-00746-4>.
33. Gavriatopoulou, Maria, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, et al. 2021. "Poor Neutralizing Antibody Responses in 106 Patients with WM after Vaccination against SARS-COV-2: A Prospective Study." *Blood Advances* 5(21): 4398–4405. <https://doi.org/10.1182/bloodadvances.2021005444>.
34. Ghione, Paola, Juan J. Gu, Kristopher Attwood, Pallawi Torka, Shipra Goel, Suchitra Sundaram, Cory Mavis, et al. 2021. "Impaired Humoral Responses to Covid-19

- Vaccination in Patients with Lymphoma Receiving B-Cell–Directed Therapies.” *Blood* 138(9): 811–14. <https://doi.org/10.1182/blood.2021012443>.
35. Guglielmelli, Paola, Alessio Mazzoni, Laura Maggi, Seble Tekle Kiros, Lorenzo Zammarchi, Sofia Pileri, Arianna Rocca, et al. 2021. “Impaired Response to First SARS-CoV-2 Dose Vaccination in Myeloproliferative Neoplasm Patients Receiving Ruxolitinib.” *American Journal of Hematology* 96 (11): E408–10. <https://doi.org/10.1002/ajh.26305>.
 36. Herishanu, Yair, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, et al. 2021 “Efficacy of the BNT162B2 Mrna COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.” *Blood* 137(23):3165–73. <https://doi.org/10.1182/blood.2021011568>.
 37. Jurgens, Eric Matthew, Thomas Joseph Ketas, Zhen Zhao, Michael Satlin, Catherine Butkus Small, Ashley Sukhu, Erik Francomano, et al. 2021. “Serologic Response to Mrna Covid - 19 Vaccination in Lymphoma Patients.” *American Journal of Hematology* 96(11). <https://doi.org/10.1002/ajh.26322>.
 38. Lim, Sean H, Nicola Campbell, Marina Johnson, Debora Joseph-Pietras, Graham P Collins, Ann O'Callaghan, Christopher P Fox, et al. 2021 “Antibody Responses after SARS-COV-2 Vaccination in Patients with Lymphoma.” *The Lancet Haematology* 8(8). [https://doi.org/10.1016/s2352-3026\(21\)00199-x](https://doi.org/10.1016/s2352-3026(21)00199-x).

39. Mairhofer, Mario, Lea Kausche, Sabine Kaltenbrunner, Riad Ghanem, Maike Stegemann, Katharina Klein, Maria Pammer, et al. 2021. “Humoral and Cellular Immune Responses in SARS-COV-2 Mrna-Vaccinated Patients with Cancer.” *Cancer Cell* 39(9): 1171–72. <https://doi.org/10.1016/j.ccell.2021.08.001>.
40. Malard, Florent, Béatrice Gaugler, Joel Gozlan, Lucie Bouquet, Djeneba Fofana, Lama Siblany, Deborah Eshagh, et al. 2021. “Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients with Hematologic Malignancies.” *Blood Cancer Journal* 11 (8): 1–8. <https://doi.org/10.1038/s41408-021-00534-z>.
41. Marasco, Vincenzo, Cristiana Carniti, Anna Guidetti, Lucia Farina, Martina Magni, Rosalba Miceli, Ludovica Calabretta, et al. 2021. “T-Cell Immune Response after Mrna Sars-Cov-2 Vaccines Is Frequently Detected Also in the Absence of Seroconversion in Patients with Lymphoid Malignancies.” *British Journal of Haematology* 196, no. 3: 548–58. <https://doi.org/10.1111/bjh.17877>.
42. Marchesi, Francesco, Fulvia Pimpinelli, Eleonora Sperandio, Elena Papa, Paolo Falcucci, Martina Pontone, Simona di Martino, et al. 2022. “The 12-Week Kinetics of Anti-SARS-CoV-2 Antibodies in Different Haematological Cancers after Vaccination with BNT162b2.” *British Journal of Haematology* 196 (2): 362–67. <https://doi.org/10.1111/bjh.17821>.
43. McKenzie, Duncan R., Miguel Muñoz-Ruiz, Leticia Monin, Thanussuyah Alaguthurai, Thomas Lechmere, Sultan Abdul-Jawad, Carl Graham, et al. 2021. “Humoral and Cellular Immunity to Delayed Second Dose of SARS-COV-2 bnt162b2 Mrna Vaccination in Patients with Cancer.” *Cancer Cell* 39(11): 1445–47. <https://doi.org/10.1016/j.ccell.2021.10.003>.

44. Monin, Leticia, Adam G. Laing, Miguel Muñoz-Ruiz, Duncan R. McKenzie, Irene del Molino del Barrio, Thanussuyah Alaguthurai, Clara Domingo-Vila, et al. 2021. "Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study." *The Lancet Oncology* 22 (6): 765–78. [https://doi.org/10.1016/S1470-2045\(21\)00213-8](https://doi.org/10.1016/S1470-2045(21)00213-8).
45. Parry, Helen, Graham McIlroy, Rachel Bruton, Sarah Damery, Grace Tyson, Nicola Logan, Chris Davis, et al. 2022. "Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients with B Cell Chronic Lymphocytic Leukaemia." *Journal of Hematology and Oncology* 15 (1): 1–12. <https://doi.org/10.1186/s13045-021-01219-7>.
46. Parry, H., G. McIlroy, R. Bruton, M. Ali, C. Stephens, S. Damery, A. Otter, et al. 2021. "Antibody Responses after First and Second Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia." *Blood Cancer Journal* 11 (7): 4–11. <https://doi.org/10.1038/s41408-021-00528-x>.
47. Peeters, M., L. Verbruggen, L. Teuwen, G. Vanhoutte, S. Vande Kerckhove, B. Peeters, S. Raats, et al. 2021. "Reduced Humoral Immune Response after BNT162b2 Coronavirus Disease 2019 Messenger RNA Vaccination in Cancer Patients under Antineoplastic Treatment." *ESMO Open* 6 (5): 100274. <https://doi.org/10.1016/j.esmoop.2021.100274>.
48. Perry, C., E. Luttwak, R. Balaban, G. Shefer, M. M. Morales, A. Aharon, Y. Tabib, et al. 2021. "Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma." *Blood Advances* 5 (16): 3053–61. <https://doi.org/10.1182/bloodadvances.2021005094>.

49. Pimpinelli, Fulvia, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Martina Pontone, et al. 2021. "Fifth-Week Immunogenicity and Safety of Anti-SARS-CoV-2 BNT162b2 Vaccine in Patients with Multiple Myeloma and Myeloproliferative Malignancies on Active Treatment: Preliminary Data from a Single Institution." *Journal of Hematology and Oncology* 14 (1): 1–12. <https://doi.org/10.1186/s13045-021-01090-6>.
50. Rahav, Galia, Yaniv Lustig, Jacob Lavee, Ohad Benjamini, Hila Magen, Tammy Hod, Noga Shem-Tov, et al. 2021. "BNT162b2 mRNA COVID-19 Vaccination in Immunocompromised Patients: A Prospective Cohort Study." *EClinicalMedicine* 41 (July): 101158. <https://doi.org/10.1016/j.eclinm.2021.101158>.
51. Schiller Salton, Neta, Moran Szwarcwort, Inna Tzoran, Netanel A. Horowitz, Tsila Zuckerman, Nurit Horesh, Yael Shachor-Meyouhas, Khetam Hussein, and Noa Lavi. 2021. "Attenuated Humoral Immune Response Following Anti-Sars-Cov -2 Vaccine in Heavily Pretreated Patients with Multiple Myeloma and Al Amyloidosis." *American Journal of Hematology* 96(12). <https://doi.org/10.1002/ajh.26373>.
52. Shem-Tov, Noga, Ronit Yerushalmi, Ivetta Danylesko, Vladislav Litachevsky, Itzhak Levy, Liraz Olmer, Yaniv Lusitg, et al. 2022. "Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Haematopoietic Stem Cell Transplantation Recipients." *British Journal of Haematology* 196 (4): 884–91. <https://doi.org/10.1111/bjh.17918>.

53. Shen, Yandong, Jane A. Freeman, Juliette Holland, Ann Solterbeck, Kartik Naidu, Asha Soosapilla, Paul Downe, et al. 2022. "Covid-19 Vaccine Failure in Chronic Lymphocytic Leukaemia and Monoclonal b-Lymphocytosis; Humoural and Cellular Immunity." *British Journal of Haematology* 197(1): 41–51. <https://doi.org/10.1111/bjh.18014>.
54. Bitoun, Samuel, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, et al. 2021. "Response to COVID-19 mRNA Vaccination in Multiple Myeloma Is Conserved but Impaired Compared to Controls." *Journal of Hematology and Oncology* 14 (1): 2–5. <https://doi.org/10.1186/s13045-021-01183-2>.
55. Terpos, Evangelos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, Ioannis Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, et al. 2021. "Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study." *Cancers* 13 (17). <https://doi.org/10.3390/cancers13174480>.
56. Terpos, Evangelos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, et al. 2021. "The Neutralizing Antibody Response Post COVID-19 Vaccination in Patients with Myeloma Is Highly Dependent on the Type of Anti-Myeloma Treatment." *Blood Cancer Journal* 11(8). <https://doi.org/10.1038/s41408-021-00530-3>.
57. Terpos, Evangelos, Ioannis P. Trougakos, Maria Gavriatopoulou, Ioannis Papassotiriou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Eleni Dimitra Papanagnou, Despina Fotiou, Efstathios Kastritis, and Meletios A. Dimopoulos. 2021. "Low Neutralizing Antibody

- Responses against SARS-CoV-2 in Older Patients with Myeloma after the First BNT162b2 Vaccine Dose.” *Blood* 137 (26): 3674–76. <https://doi.org/10.1182/blood.2021011904>.
58. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, and Pradhan K. 2021. “Seroconversion Rates Following COVID-19 Vaccination among Patients with Cancer.” *Cancer Cell*, no. January.
59. Herzog Tzarfati, Katrin, Odit Gutwein, Arie Apel, Naomi Rahimi-Levene, Maya Sadovnik, Lotem Harel, Patricia Benveniste-Levkovitz, Adina Bar Chaim, and Maya Koren-Michowitz. 2021. “BNT162b2 COVID-19 Vaccine Is Significantly Less Effective in Patients with Hematologic Malignancies.” *American Journal of Hematology* 96 (10): 1195–1203. <https://doi.org/10.1002/ajh.26284>.
60. Oekelen, Oliver Van, Charles R. Gleason, Sarita Agte, Komal Srivastava, Katherine F. Beach, Adolfo Aleman, Katerina Kappes, et al. 2021. “Highly Variable SARS-CoV-2 Spike Antibody Responses to Two Doses of COVID-19 RNA Vaccination in Patients with Multiple Myeloma.” *Cancer Cell* 39 (8): 1028–30. <https://doi.org/10.1016/j.ccell.2021.06.014>.
61. Greenberg, Ross S., Jake A. Ruddy, Brian J. Boyarsky, William A. Werbel, Jacqueline M. Garonzik-Wang, Dorry L. Segev, and Philip H. Imus. 2021. “Safety and Antibody Response to Two-Dose SARS-COV-2 Messenger RNA Vaccination in Patients with Multiple Myeloma.” *BMC Cancer* 21(1). <https://doi.org/10.1186/s12885-021-09097-5>.
62. Noori, Maryam, Shadi Azizi, Farhan Abbasi Varaki, Seyed Aria Nejadghaderi, and Davood Bashash. 2022. “A Systematic Review and Meta-Analysis of Immune Response against First and Second Doses of SARS-COV-2 Vaccines in Adult Patients with Hematological

Malignancies.” *International Immunopharmacology* 110: 109046.
<https://doi.org/10.1016/j.intimp.2022.109046>.

63. Dhakal, Binod, Sameem Abedin, Timothy Fenske, Saurabh Chhabra, Nathan Ledebor, Parameswaran Hari, and Mehdi Hamadani. 2021. “Response to SARS-CoV-2 Vaccination in Patients after Hematopoietic Cell Transplantation and CAR T-Cell Therapy.” *Blood* 138 (14): 1278–81. <https://doi.org/10.1182/blood.2021012769>.
64. Marra, Alexandre R., Takaaki Kobayashi, Hiroyuki Suzuki, Mohammed Alsuhaibani, Bruna Marques Tofaneto, Luigi Makowski Bariani, Mariana de Auler, et al. 2021. “Short-Term Effectiveness of Covid-19 Vaccines in Immunocompromised Patients: A Systematic Literature Review and Meta-Analysis.” *Journal of Infection* 84(3):297–310. <https://doi.org/10.1016/j.jinf.2021.12.035>.